MedTrace Logo

Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma

NCT01676649 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-02-18

No results posted yet for this study

Summary

The safety of the combination of ipilimumab with carboplatin/paclitaxel treatment with two different dosing schedules will be investigated in patients with metastatic melanoma. This protocol will also investigate both the clinical benefit of this combination and the features of the host immune system that may predict response to ipilimumab with chemotherapy in patients with unresectable Stage III and Stage IV melanoma.

Conditions

  • Untreated Stage III Melanoma or Stage IV Melanoma

Interventions

BIOLOGICAL

Ipilimumab

3 mg/kg

DRUG

Carboplatin

AUC = 6

DRUG

Paclitaxel

175 mg/m2

Sponsors & Collaborators

  • Jewish General Hospital

    lead OTHER

Principal Investigators

  • Wilson Miller, MD, PhD · Jewish General Hospital

  • Rahima Jamal, MD · Notre-Dame Hospital (CHUM)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2017-02-28
Completion
2026-05-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01676649 on ClinicalTrials.gov